ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO665

The Factors for Maintenance of B Cell Depletion After Use of Rituximab in Renal Disorders

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Yu, Binfeng, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
  • Han, Fei, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Background

The duration of B-cell depletion(BCD) after rituximab administration may be related to the disease recurrence. We aimed to explore the factors which may influence the duration of BCD(CD19 positive B cell count<5/μL) after the use of rituximab in patients with kidney diseases.

Methods

Patients received rituximab for renal causes and were regularly monitored every 2-3 months on B cell counts were enrolled. Prognostic factors for maintenance of BCD were identified through Cox proportional hazards model where the optimal cutoff values were determined using an online statistical tool Cutoff Finder.

Results

There were 47 patients who received a median of 900mg (range,300-1500mg) of rituximab with 100% achieving BCD and 49% experiencing B cell reconstitution during follow-up. The optimal cutoff value of dose to body-surface-area ratio (DBR) was 529.5mg/m2 in total and that of circulating T helper (Th) cell count was 978.5/μL. In multivariate analyses, high DBR(>529.5mg/m2) was identified as an independent protective factor (HR0.42,p=0.024) and high circulating Th cell count (>978.5/μL) was identified as an independent risk factor (HR2.98,p=0.037) for maintenance of BCD. High Th cell count (>978.5/μL) was also associated with manifestation of nephrotic syndrome, increased CD19 positive B cell counts and T killer cell counts.

Conclusion

DBR and Th cell counts were of predictive values for maintenance of BCD after use of rituximab in patients with renal disorders.

Prognostic parameters for maintenance of B cell depletion (BCD) via Cox proportional hazards model

Funding

  • Government Support - Non-U.S.